Bexarotene
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-BEXAROTENE |
|---|---|
| Type | Drug |
| Aliases | TargretinБексаротен |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-MF-SEZARY |
| Sources | SRC-ESMO-CTCL-2024 SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Selective retinoid X receptor (RXR) agonist |
|---|---|
| Mechanism | Selectively binds and activates retinoid X receptors (RXRα, RXRβ, RXRγ), which heterodimerize with other nuclear receptors to regulate gene expression involved in cellular differentiation and proliferation. In CTCL induces apoptosis and differentiation of malignant T-cells. |
| Typical dosing | PO: 300 mg/m² once daily with meal. Topical 1% gel: apply to lesions every other day, increase to 4×/day as tolerated. |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Warnings
- Major birth defects — pregnancy must be excluded; effective contraception ≥1 month before, during, and ≥1 month after therapy
- Severe hypertriglyceridemia / pancreatitis — baseline + monthly fasting lipid panel
Notes
Duvic 2001 phase 2/3 in r/r CTCL — ORR ~45-55% (any stage), durable in maintenance setting. FDA-approved for CTCL refractory to ≥1 prior line. Triglyceride and thyroid management are the dominant practical challenges — atorvastatin or fenofibrate prophylaxis usually started concurrently; levothyroxine empirically considered. Topical gel useful for limited skin lesions. Major UA access barrier — international supply required.
Used By
Regimens
REG-BEXAROTENE-MAINTENANCE-CTCL- Bexarotene low-dose maintenance for CTCL responders (75-150 mg/m² PO daily)REG-BEXAROTENE-MONO-CTCL- Bexarotene PO monotherapy for CTCL (300 mg/m² daily, continuous)